Laura Francis

“We delivered a solid third quarter with accelerating procedure demand, broader physician adoption, and improving financial Thank you. These results reflect disciplined execution of our multi-year strategy to expand our differentiated platform into new clinical applications.”

“Our second quarter results demonstrate the strength of our core competencies and the momentum they've created in the business.”

“In the first quarter, we advanced our platform strategy on multiple fronts. Underpinning these strategic priorities is our clear focus on developing disruptive technologies that address unmet clinical needs for surgeons and interventionalists when treating patients with compromised bone.”

“Our strong fourth quarter and full year 2025 results validate that our innovation-led growth strategy is delivering meaningful, real-world impact. We built deep technical expertise to solve complex procedural challenges that historically led to poor outcomes for patients with compromised bone.”

“In the third quarter, we continued to advance our vision to provide better outcomes for patients with compromised bone. Our strong performance in the quarter reflects the continuation of healthy demand trends and our disciplined execution over the last several quarters.”